Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25073714 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Krzysztof Laudanski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Care, Mayo Clinic, Rochester, MN 55902, USA. Hauptthemen laut MEDLINE: COVID-19, HMGB1 Protein. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NIH.
Abstract (Originalsprache)
This research analyzes immunological response patterns to SARS-CoV-2 infection in blood and urine in individuals with serum cotinine-confirmed exposure to nicotine. Samples of blood and urine were obtained from a total of 80 patients admitted to hospital within 24 h of admission (tadm), 48 h later (t48h), and 7 days later (t7d) if patients remained hospitalized or at discharge. Serum cotinine above 3.75 ng/mL was deemed as biologically significant exposure to nicotine. Viral load was measured with serum SARS-CoV-2 S-spike protein. Titer of IgG, IgA, and IgM against S- and N-protein assessed specific antiviral responses. Cellular destruction was measured by high mobility group box protein-1 (HMGB-1) serum levels and heat shock protein 60 (Hsp-60). Serum interleukin 6 (IL-6), and ferritin gauged non-specific inflammation. The immunological profile was assessed with O-link. Serum titers of IgA were lower at tadm in smokers vs. nonsmokers (p = 0.0397). IgM at t48h was lower in cotinine-positive individuals (p = 0.0188). IgG did not differ between cotinine-positive and negative individuals. HMGB-1 at admission was elevated in cotinine positive individuals. Patients with positive cotinine did not exhibit increased markers of non-specific inflammation and tissue destruction. The blood immunological profile had distinctive differences at admission (MIC A/B↓), 48 h (CCL19↓, MCP-3↓, CD28↑, CD8↓, IFNγ↓, IL-12↓, GZNB↓, MIC A/B↓) or 7 days (CD28↓) in the cotinine-positive group. The urine immunological profile showed a profile with minimal overlap with blood as the following markers being affected at tadm (CCL20↑, CXCL5↑, CD8↑, IL-12↑, MIC A/B↑, GZNH↑, TNFRS14↑), t48h (CCL20↓, TRAIL↓) and t7d (EGF↑, ADA↑) in patients with a cotinine-positive test. Here, we showed a distinctive immunological profile in hospitalized COVID-19 patients with confirmed exposure to nicotine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Perioperative Care, Mayo Clinic, Rochester, MN 55902, USA.
- Department of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN 55902, USA.
- Department of Nephrology, University of Pennsylvania, Philadelphia, PA 19146, USA.
- School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, USA.
ORCID-Profile: Krzysztof Laudanski, Mohamed A Mahmoud
Förderung
- NIGMS NIH HHS
- NIDDK NIH HHS
- NIH
- Mayo Clinic internal fund
Zitieren
APA
Laudanski, K., Mahmoud, M. A., Ahmed, A. S., Susztak, K., Mathew, A., & Chen, J. (2024). Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25073714
Vancouver
Laudanski K, Mahmoud MA, Ahmed AS, Susztak K, Mathew A, Chen J. Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25073714
BibTeX
@article{Laudanski2024,
author = {Laudanski, Krzysztof and Mahmoud, Mohamed A and Ahmed, Ahmed Sayed and Susztak, Kaitlin and Mathew, Amal and Chen, James},
title = {Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25073714}
}
EUVIMED